论文部分内容阅读
目的 探讨可溶性尿激酶型纤溶酶原激活物受体(suPAR)、降钙素原(PCT)及C反应蛋白(CRP)在支气管扩张症(支扩)继发感染患者血清中的表达.方法 采用ELISA法、酶联荧光分析、单向免疫扩散法及血细胞自动分析仪分别检测40例支扩继发感染患者(A组)治疗前及治疗第14天血清suPAR、PCT、CRP水平及WBC值,并与38例健康体检者(C组)比较.结果 治疗前,A组血清suPAR、PCT、CRP及WBC水平高于C组(P＜0.01).与治疗前比较,A组治疗第14天时血清suPAR、PCT、CRP及WBC水平降低(P＜0.01).A组治疗前,血清suPAR、PCT和CRP与WBC呈正相关(r=0.754、0.658和0.735,P＜0.01),血清suPAR与PCT和CRP呈正相关(r=0.894和0.865,P＜0.01).结论 联合检测和动态监测血清suPAR、PCT及CRP对评估支扩继发感染患者感染的严重程度和制定治疗方案有重要临床意义.“,”Objective To explore the expressions of serum soluble urokinase plasminogen activator(suPAR),procalcitonin(PCT) and C-reactive protein(CRP) in bronchiectasis patients with secondary infection.Methods WBC count and serum suPAR,PCT,CRP were detected by ELISA in bronchiectasis patients with secondary infection(group A,40 cases) before and on the 14th day after treatment.The results were compared with those in healthy people (group C,38 cases).Results Before treatment,the levels of suPAR,PCT,CRP and WBC were higher in group A than those in group C(P＜0.01),which in group A were significantly decreased on the 14th day after treatment compared to those before(P＜0.01).Before treatment,serum levels of suPAR,PCT and CRP in group A were positively correlated to WBC count (r =0.754,0.658 and 0.735,P＜0.01).Serum level of suPAR in group A was positively correlated to that of PCT and CRP(r=0.894 and 0.865,P＜0.01).Conclusion Combined detection and dynamic monitoring of serum suPAR,PCT and CRP in bronchiectasis patients with secondary infection have a significant clinical value in evaluating the severity of disease and making plan for the treatments.